Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas

Abstract

Background: Prognostic factors and the standard treatment approach for gynaecological carcinosarcomas have not yet been clearly defined. Although carcinosarcomas are more aggressive than pure epithelial tumours, they are treated similarly. Serous/clear cell and endometrioid components may be predictive factors for the efficacy of adjuvant chemotherapy (CT) or radiotherapy (RT) or RT in patients with uterine and ovarian carcinosarcomas. Heterologous carcinosarcomas may benefit more from adjuvant CT.

Aims: We aimed to define the prognostic and predictive factors associated with treatment options in ovarian (OCS) and uterine carcinosarcoma (UCS).

Study Design: Retrospective cross-sectional study

Methods: We retrospectively reviewed the medical records of patients with ovarian and uterine carcinosarcoma from 2000 to 2013, and 127 women were included in this study (24 ovarian and 103 uterine). Patients admitted to seventeen oncology centres in Turkey between 2000 and December 2013 with a histologically proven diagnosis of uterine carcinosarcoma with FIGO 2009 stage I-III and patients with sufficient data obtained from well-kept medical records were included in this study. Stage IV tumours were excluded. The patient records were retrospectively reviewed. Data from 104 patients were evaluated for this study.

Results: Age (>= 70 years) was a poor prognostic factor for UCS (p=0.036). Pelvic +/- para aortic lymph node dissection did not affect overall survival (OS) (p=0.35). Macroscopic residual disease was related with OS (p<0.01). The median OS was significantly longer in stage I-II patients than stage III patients (p=0.03). Adjuvant treatment improved OS (p=0.013). Adjuvant radiotherapy tended to increase the median OS (p=0.075). However, this tendency was observed in UCS (p=0.08) rather than OCS (p=0.6). Adjuvant chemotherapy had no effect on OS (p=0.15). Adjuvant radiotherapy significantly prolonged the median OS in patients with endometrioid component (p=0.034). A serous/clear cell component was a negative prognostic factor (p=0.035). Patients with serous/clear cell histology for whom adjuvant chemotherapy was applied had significantly longer OS (p=0.019), and there was no beneficial effect of adjuvant radiotherapy (p=0.4). Adjuvant chemotherapy was effective in heterologous tumours (p=0.026). In multivariate analysis, the stage and chemotherapy were prognostic factors for all patients. Age was an independent prognostic factor for UCS. However, serous/clear cell histology and radiotherapy tended to be significant prognostic factors.

Conclusion: The primary location, the histological type of sarcomatous and the epithelial component may be predictive factors for the efficacy of chemotherapy or radiotherapy in UCS and OCS.

C1 [Cicin, Irfan; Turkmen, Esma; Erdogan, Bulent; Hacioglu, M. Bekir] Trakya Univ, Sch Med, Dept Med Oncol, Edirne, Turkey.

[Ozatli, Tahsin; Gokdurnali, Ayse; Oksuzoglu, Berna] Ankara Dr Abdurrahman Yurtaslan Oncol Training &, Dept Med Oncol, Ankara, Turkey.

[Ozturk, Turkan] Karadeniz Tech Univ, Dept Med Oncol, Sch Med, Trabzon, Turkey.

[Ozcelik, Melike; Balvan, Ozlem] Dr Lutfi Kirdar Res & Training Hosp, Dept Med Oncol, Istanbul, Turkey.

[Cabuk, Devrim] Kocaeli Univ, Sch Med, Dept Med Oncol, Kocaeli, Turkey.

[Yildiz, Yasar] Ataturk Training & Res Hosp, Dept Med Oncol, Izmir, Turkey.

[Seker, Metin] Cumhuriyet Univ, Dept Med Oncol, Sch Med, Sivas, Turkey.

[Ozdemir, Nuriye] Ankara Numune Training & Res Hosp, Dept Med Oncol, Ankara, Turkey.

[Yapar, Burcu] Pamukkale Univ, Dept Med Oncol, Sch Med, Denizli, Turkey.

[Tanriverdi, Ozgur] Mugla Univ, Dept Med Oncol, Sch Med, Mugla, Turkey.

[Gunaydin, Yusuf] Gazi Univ, Dept Med Oncol, Sch Med, Ankara, Turkey.

[Menekse, Serkan] Celal Bayar Univ, Dept Med Oncol, Sch Med, Manisa, Turkey.

[Aksoy, Asude] Inonu Univ, Dept Med Oncol, Sch Med, Malatya, Turkey.

[Arpaci, Erkan] Sakarya Res & Training Hosp, Dept Med Oncol, Sakarya, Turkey.

[Sevinc, Alper] Gaziantep Univ, Dept Med Oncol, Sch Med, Gaziantep, Turkey.